November 7, 2016 / 11:07 PM / 9 months ago

BRIEF-Adalta enters into commercialisation agreement with crossbeta biosciences

Nov 8 (Reuters) - Adalta Ltd :

* Commercialisation agreement with crossbeta biosciences

* Will receive royalties on future revenues from commercialization of aßo-specific shark antibodies as novel therapeutics or diagnostic agents

* Under terms of agreement, crossbeta has been granted an exclusive license to three beta-amyloid oligomer (aßo)-specific shark antibodies

Source text for Eikon:

Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below